Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

(Amendment No. ___)*

 

Under the Securities Exchange Act of 1934

 

 

CITIUS PHARMACEUTICALS, INC.

(Name of Issuer)

 

 

Common Stock, $0.001 Par Value

(Title of Class of Securities)

 

17322U207

(CUSIP Number)

 

Myron Z. Holubiak

11 Commerce Drive, 1^st Floor

Cranford, New Jersey 07016

(908) 967-6676

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

August 13, 2018

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule l3G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 17322U207

Page 2 of 6

 

1.	Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only)   Myron Z. Holubiak
2.	Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ Not Applicable
3.	SEC Use Only
4.	Source of Funds (See Instructions)   PF
5.	Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)   Not Applicable
6.	Citizenship or Place of Organization   United States

Number of Shares Beneficially Owned By Each Reporting Person with	7.	Sole Voting Power   2,149,236(1)
	8.	Shared Voting Power   0
	9.	Sole Dispositive Power   2,149,236
	10.	Shared Dispositive Power   0

11.	Aggregate Amount Beneficially Owned by Each Reporting Person   2,149,236
12.	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares   ☐
13.	Percent of Class Represented by Amount in Row (11)   12.6%(2)
14.	Type of Reporting Person   IN

 

⁽¹⁾ Includes as of August 13, 2018, (i) 803,929 shares of Common Stock, par value $0.001 per share (the "Common Stock") of Citius Pharmaceuticals, Inc. (the "Issuer") issuable upon the exercise of currently exercisable warrants, and (ii) 41,111 shares of Common Stock subject to options held by Myron Z. Holubiak (the "Reporting Person") that are exercisable within 60 days of August 13, 2018.

 

⁽²⁾ The calculation is based on 16,198,791 shares of Common Stock of the Issuer outstanding as of August 13, 2018, according to information set forth in the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2018 ("Form 10-Q"), filed with the U.S. Securities and Exchange Commission (the "Commission") on August 14, 2018.

 

 

CUSIP No. 17322U207

Page 3 of 6

 

Item 1.

Security and Issuer

 

This statement on Schedule 13D relates to the Common Stock of the Issuer. The Issuer’s principal executive office is located at 11 Commerce Drive, 1^st Floor, Cranford, New Jersey 07016.

 

Item 2.

Identity and Background

 

(a) This Schedule 13D is being filed on behalf of the Reporting Person pursuant to Rule 13d-1 of Regulations D-G under the Act.

 

(b) The Reporting Person’s business address is 11 Commerce Drive, 1^st Floor, Cranford, New Jersey 07016.

 

(c) The principal occupation of the Reporting Person is that of Chief Executive Officer and President of the Issuer.

 

(d) – (e) During the last five years, the Reporting Person: (i) has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors); and (ii) has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in his being subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

(f) The Reporting Person is a citizen of the United States of America.

 

Item 3.

Source and Amount of Funds or Other Consideration.

 

The share and dollar amounts reported below for transactions prior to June 9, 2017 do not give effect to the 1-for-15 reverse stock split of the Issuer’s Common Stock effected by the Issuer on June 9, 2017 (the “Reverse Stock Split”).

 

On June 12, 2014, the Reporting Person was granted a five-year warrant to purchase 162,500 shares of Leonard-Meron Biosciences, Inc. Series A Preferred Stock at an exercise price of $0.75 per share. Pursuant to the Merger Agreement (as defined below), the warrant was converted into a warrant to purchase 294,217 shares of the Issuer’s Common Stock at a per share exercise price of $0.41.

 

On October 1, 2015, the Reporting Person was granted an option to purchase 400,000 shares of Common Stock of the Issuer at a purchase price of $0.54 per share pursuant to the Issuer’s 2014 Stock Incentive Plan. The option is fully vested.

 

On March 30, 2016, the Issuer, Citius LMB Acquisition Corp. and Leonard-Meron Biosciences, Inc. entered into an Agreement and Plan of Merger (the “Merger Agreement”). As a result of the merger, Reporting Person was issued 7,754,497 shares of the Issuer’s Common Stock.

 

 

CUSIP No. 17322U207

Page 4 of 6

 

On June 9, 2017, the Issuer effected the Reverse Stock Split, immediately after which Reporting Person owned 516,967 shares of Common Stock, options to purchase 26,667 shares of Common Stock, and a warrant to purchase 19,615 shares of Common Stock.

 

On September 15, 2017, the Reporting Person was granted an option to purchase 41,111 shares of Common Stock of the Issuer at a purchase price of $3.45 per share. One-third of the options vest on September 13, 2018, with the remainder vesting monthly for the two years following the initial vesting.

 

On March 28, 2018, the Reporting Person purchased on the open market 2,915 shares of the Issuer’s Common Stock at a purchase price of $3.09 per share.

 

On August 13, 2018, the Reporting Person purchased 784,314 shares of the Issuer’s Common Stock and a warrant for up to 784,314 shares of the Issuer’s Common Stock at a price per unit of $1.275, which was the price per unit paid by other investors in the Issuer’s registered offering.

 

Item 4.

Purpose of Transaction.

 

The Reporting Person obtained the shares of Common Stock and warrants to purchase Common Stock of the Issuer for investment purposes and obtained the options to purchase Common Stock as compensation from the Issuer in his position as Chief Executive Officer. The Reporting Person does not have any present plans or proposals that relate to or would result in: (i) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (ii) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of the Issuer’s subsidiaries; (iii) a sale or transfer of a material amount of assets of the Issuer or any of the Issuer’s subsidiaries; (iv) any change in the present board of directors or management of the Issuer; (v) any material change in the present capitalization or dividend policy of the Issuer; (vi) any other material change in the Issuer’s business or corporate structure; (vii) changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (viii) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (ix) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (x) any action similar to any of those enumerated above.

 

Item 5.

Interest in Securities of the Issuer.

 

(a)

 

The Reporting Person is the beneficial owner of an aggregate of 2,149,236 shares of the Issuer’s Common Stock, which represents approximately 12.6% of the Issuer’s outstanding Common Stock based upon 16,198,791 shares of Common Stock outstanding as of August 13, 2018, as provided by the Issuer in its Form 10-Q.

 

The Reporting Person’s beneficial ownership consists of (i) 1,304,196 shares of the Issuer’s Common Stock, (ii) 803,929 shares of the Issuer’s Common Stock issuable upon the exercises of currently-exercisable warrants, and (iii) 41,111 shares of the Issuer’s Common Stock subject to options held by the Reporting Person that are exercisable within 60 days of August 13, 2018.

 

 

CUSIP No. 17322U207

Page 5 of 6

 

(b)

 

The Reporting Person has sole voting and dispositive power of 2,149,236 shares of the Issuer’s Common Stock beneficially owned.

 

(c)

 

On August 13, 2018, the Reporting Person purchased 784,314 shares of the Issuer’s Common Stock and a warrant for up to 784,314 shares of the Issuer’s Common Stock at a price per unit of $1.275, which was the price per unit paid by other investors in the Issuer’s registered offering.

 

(d) Except as described in this statement, no person has the power to direct the receipt of dividends on or the proceeds of sales of, the shares of the Issuer’s Common Stock owned by the Reporting Person.

 

(e) Not Applicable.

 

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

The Reporting Person has purchased from the Issuer warrants to purchase an aggregate of 803,929 shares of the Issuer’s Common Stock at varying exercise prices, with a weighted average price of $1.272 per share. All of the warrants are currently exercisable, but some expire as early as June 12, 2019 while others will not expire until August 14, 2023. Forms of the warrants held by the Reporting Person have been filed as exhibits to the Issuer’s periodic reports filed with the Commission.

 

Item 7.

Materials to be Filed as Exhibits.

 

Not applicable.

 

 

CUSIP No. 17322U207

Page 6 of 6

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: August 27, 2018

 

	/s/ Myron Z. Holubiak
	Myron Z. Holubiak